Clinical trials: Pulmonary Artery Hypertension
Hypertension, Pulmonary
A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension
To evaluate the effect of three doses of oral sildenafil (20, 40 and 80 mg three times a day [TID]) on exercise capacity, as measured by the 6-Minute Walk test, as well as the safety and tolerability, after 12 weeks of treatment…
- Trial name
- NCT00644605
- Testing
- sildenafil
- Where
- 68 sites in United States, Australia and 21 more
- Volunteers
- 275 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Takayasu Arteritis, Pulmonary Artery Hypertension
Pulmonary Artery Involvement in Takayasu's Arteritis
The purpose of this study is to analyze the clinical manifestations, imaging features, and prognosis-related factors of pulmonary artery (PA) involvement in Takayasu's arteritis (TA), and to explore the early clinical features of…
- Trial name
- NCT03189602
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Peking Union Medical College Hospital
Pulmonary Arterial Hypertension
Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine
This study will compare the bioavailability and pharmacokinetics of the 0.5 mg, 1 mg and 2.5 mg treprostinil diethanolamine tablet strengths in healthy volunteers.
- Trial name
- NCT01153386
- Testing
- Treprostinil diethanolamine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- United Therapeutics
Pulmonary Hypertension, Mitral Valve Disease
Symptomatic Pulmonary Arterial Hypertension After Mitral Valve Surgery
Most patients with mitral valve disease are symptomatic with shortness of breath and a limited activity level prior to mitral valve surgery.
- Trial name
- NCT01646541
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Duke University
Pulmonary Arterial Hypertension
Combination Therapy in Pulmonary Arterial Hypertension
An open label, non-comparative study design is appropriate for this Phase 4 study designed to assess whether a core therapy of bosentan, either as monotherapy or with the addition of sildenafil, enables patients with pulmonary…
- Trial name
- COMPASS 3 (NCT00433329)
- Testing
- Bosentan, Sildenafil
- Volunteers
- 100 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil
The purpose of this study is to provide Sildenafil therapy for subjects who completed A1481156 study and are judged by the investigator to derive clinical benefit from continued treatment with Sildenafil, prior to reimbursement…
- Trial name
- NCT01897740
- Testing
- sildenafil
- Where
- Russia
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension
Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension
In preparation for a future mechanistic study, investigators now propose to test the specific hypothesis that carnitine consumption is not reduced in PAH, that plasma carnitine levels are stable over time in PAH and that…
- Conditions
- Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension, Lung Diseases
- Trial name
- NCT04908397
- Testing
- L-carnitine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Arterial Hypertension
Bosentan in Children With Pulmonary Arterial Hypertension Extension Study
The main objective of the FUTURE 2 study was to assess the long-term safety and tolerability of the pediatric formulation of bosentan in children with idiopathic pulmonary arterial hypertension or familial pulmonary arterial…
- Trial name
- FUTURE 2 (NCT00319020)
- Testing
- Bosentan
- Volunteers
- 33 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH)
The investigators hypothesize that baseline plasma brain natriuretic peptide (BNP) and migration inhibitory factor (MIF) levels are surrogate markers of clinical severity of PAH and that changes in plasma brain natriuretic…
- Trial name
- Biomarkers (NCT00566423)
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Northwell Health
Pulmonary Hypertension
Neuromodulation in Patients With Pulmonary Arterial Hypertension
Patients with Group 1 pulmonary hypertension will be enrolled in this study. Investigators will test the hypothesis of low-level tragal stimulation in patients with pulmonary hypertension.
- Trial name
- NIP (NCT06802380)
- Testing
- Low-level tragus stimulation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Oklahoma
Intrahepatic Cholangiocarcinoma (Icc)
Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (ICC), the second most prevalent primary malignant liver neoplasm, features highly aggressive biological behavior and dismal prognosis.
- Trial name
- LPHAIC for ICC (NCT07646717)
- Testing
- hepatic arterial infusion chemotherapy (Irinotecan liposome plus 5-FU/LV) combined with lenvatinib and PD-1 inhibitors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pulmonary Hypertension
Acute Exposure to High Altitude on Pulmonary Artery Pressure and Right Heart Function (Echo)
Randomized crossover Trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to High Altitude ("Säntis"; 2500m above sea level) on pulmonary artery pressure and right heart function (echo)
- Trial name
- NCT03637166
- Testing
- Assessment at Low Altitude (470m above sea level), Exposure to High Altitude (2500m above sea level)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Persistent Pulmonary Hypertension, Respiratory Distress Syndrome
Treatment of Elevated Arterial Pulmonary Pressure With Inhaled Iloprost
The purpose of this study is to determine if iloprost is effective in the treatment of elevated arterial pulmonary pressure in children with ventilator treated respiratory distress syndrome.
- Trial name
- NCT00216931
- Testing
- iloprost
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Lund University Hospital
Pulmonary Arterial Hypertension
A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
The purpose of this study to confirm the selexipag starting dose(s), selected based on pharmacokinetic (PK) extrapolation from adults, that leads to similar exposure as adults doses in children from greater than or equal to (>=)…
- Trial name
- NCT03492177
- Testing
- selexipag (Uptravi)
- Where
- 34 sites in United States, Belarus and 14 more
- Volunteers
- 63 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Peripheral Muscle Microcirculation and Exercise-induced Blood Flow Distribution in Pulmonary Arterial Hypertension
Pulmonary artery hypertension (PAH) is a rare, severe disease, characterized by a progressive increase in pulmonary vascular resistance ultimately leading to right ventricular (RV) failure and premature death.
- Trial name
- NCT01520493
- Testing
- Submaximal exercises
- Where
- 2 sites in Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Laval University
Pulmonary Arterial Hypertension
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.
- Trial name
- GRIPHON (NCT01106014)
- Testing
- Selexipag
- Where
- 182 sites in United States, Argentina and 37 more
- Volunteers
- 1,156 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension
To investigate the long-term safety and effectiveness of Adcirca (tadalafil) in Pulmonary Arterial Hypertension (PAH) patients in the clinical practice -focused topics- 1.
- Trial name
- NCT01066845
- Testing
- tadalafil
- Volunteers
- 1,809 people
- Sponsor
- Eli Lilly and Company
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc)
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment.
- Conditions
- Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms
- Trial name
- NCT05286814
- Testing
- Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
What is the Role of the Exposome in Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a rare and incurable disease affecting people of all ages. It is characterized by obstructive remodeling of the small pulmonary arteries, responsible for an increase in pulmonary arterial…
- Trial name
- EXPOSPAH (NCT07172334)
- Testing
- Questionnaires, Samples
- Where
- 10 sites in France
- Volunteers
- 150 people
- Sponsor
- Poitiers University Hospital
Pulmonary Arterial Hypertension
Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study
The main OBJECTIVE of this proposal is to extend the investigator's preclinical findings on the role of epigenetics and DNA damage and Bromodomain-Containing Protein 4 (BRD4) inhibition as a therapy for a devastating disease…
- Trial name
- APPRoAcH-p (NCT03655704)
- Testing
- Apabetalone
- Where
- 2 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Steeve Provencher